Recent data from our lab suggests that MHC II-deficient myeloma cells can be eliminated by a combinatorial regimen of CD4+ ACT and sub-lethal irradiation in the setting of established, disseminated myeloma within the bone marrow [2], although the effector cells in this setting have not been identified. Here, CD4 is linked to plasma cell myeloma.